Can-Fite BioPharma Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
Can-Fite BioPharma Ltd. (CANF) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations of 170.50 thousand shares for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations · last filed 2023-03-30
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 12 month |
|---|---|
| 2022-12-31 | 170.50K shares 20-F · filed 2023-03-30 |
| 2021-12-31 | 600.70K shares 20-F · filed 2022-03-24 |
| 2019-12-31 | 4.00K shares 20-F · filed 2021-03-25 |
| 2018-12-31 | 53.02K shares 20-F · filed 2021-03-25 |